Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PLAU | P00749 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | BLK | P51451 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819422 | 0.89 | NPC1 (0.46) | KDM4ENPC1RAB9ASMN1; SMN2CSF1R | |
| SCHEMBL13175135 | 0.85 | KDM4E (0.46) | LMNAKDM4EPLAUNPC1RAB9A | |
| SCHEMBL13135799 | 0.85 | KDM4E (0.43) | LMNAKDM4ESMN1; SMN2CSF1RKIT | |
| SCHEMBL2819183 | 0.82 | MAPT (0.49) | LMNARAB9ACSF1RKITBLK | |
| SCHEMBL12973389 | 0.81 | S1PR2 (0.52) | LMNAKDM4EPLAUNPC1RAB9A | |
| SCHEMBL2819162 | 0.80 | MKNK1 (0.41) | CSF1RKITBLK | |
| SCHEMBL2817355 | 0.78 | FLT3 (0.49) | CSF1RKITBLKMEN1KMT2A | |
| SCHEMBL2821445 | 0.78 | RIPK1 (0.48) | KDM4ENPC1RAB9ASMN1; SMN2CSF1R | |
| SCHEMBL2818505 | 0.76 | FLT3 (0.63) | — | |
| SCHEMBL2819164 | 0.75 | CSF1R (0.40) | LMNAKDM4ENPC1RAB9ACSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795264-B2 | Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-09-14 | — | — | US | claimed |
| EP-2032573-A1 | SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-11 | — | — | EP | claimed |
| US-20080064707-A1 | SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-13 | — | — | US | claimed |
| WO-2007144203-A1 | SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-21 | — | — | WO | claimed |
| EP-2061790-B1 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them | BAYER IP GMBH (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-7846928-B2 | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7846928-B2 | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7846928-B2 | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7795264-B2 | Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-09-14 | — | — | US | disclosed |
| US-7795264-B2 | Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-09-14 | — | — | US | disclosed |
| US-20080064707-A1 | SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064707-A1 | SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-13 | — | — | US | disclosed |
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| EP-1870410-A1 | Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-26 | — | — | EP | disclosed |
| EP-1870410-A1 | Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007144203-A1 | SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007144204-A1 | SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-21 | — | — | WO | disclosed |
| EP-1867648-A1 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-19 | — | — | EP | disclosed |
| EP-1867648-A1 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | KDR, TIE1, FLT1 | LMNA 3934/4885KDM4E 541/4885PLAU 2447/4885 |
| US-20080064707-A1 | SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | KDR, TIE1, TEK | LMNA 3792/4885KDM4E 346/4885PLAU 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.